Cytokinetics Inc. won US approval for a drug to treat a deadly heart condition, posing a potential threat to sales of a similar Bristol Myers Squibb Co. treatment that’s expected to be a key growth contributor for the company.
Bloomberg - Where voices unite, stories flourish, and community thrives through open dialogue and meaningful connections.
Company
Trending
Categories
© Bloombergnews. All rights resereved